|                                      | Mean (SD) or ratio |
|--------------------------------------|--------------------|
| Age (years)                          | 47 (15)            |
| Sex Ratio (M:F)                      | 1:1                |
| Symptom onset to first serum collection (days) | 54 (17)          |
| Symptom onset to last serum collection (days) | 105 (17)         |
| Time between first and last serum collection (days) | 52 (20)          |
| Symptom onset date range             | 3/3/2020 to 5/4/2020 |
### Supplemental Table 2: Longitudinal Models

|                      | Estimate (95% CI)     | P value |
|----------------------|-----------------------|---------|
| **Abbott NC IgG CIA**|                       |         |
| Days from onset      | -0.019 (-0.023, -0.016) | <0.001  |
| Intercept            | 6.802 (6.147, 7.456)   | <0.001  |
| Random Intercept SD  | 1.952 (1.579, 2.425)   | -       |
| Residual SD          | 0.405 (0.336, 0.491)   | -       |
| **Roche NC Total Ab ECLIA** |                |         |
| Days from onset      | 0.437 (0.305, 0.571)   | <0.001  |
| Intercept            | 45.121 (30.674, 59.569) | <0.001  |
| Random Intercept SD  | 31.690 (24.767, 40.191) | -       |
| Residual SD          | 16.676 (13.873, 20.167) | -       |
| **Roche RBD Total Ab ECLIA** |            |         |
| Days from onset      | 0.32 (0.02, 0.63)     | 0.036   |
| Intercept            | 135.88 (109.12, 162.64) | <0.001  |
| Random Intercept SD  | 73.29 (66.60, 80.65)  | -       |
| Residual SD          | 26.47 (21.64, 32.39)  | -       |
| **Ortho S IgG CIA**  |                       |         |
| Days from onset      | -0.036 (-0.047, -0.025) | <0.001  |
| Intercept            | 15.900 (13.953, 17.848) | <0.001  |
| Random Intercept SD  | 5.774 (4.663, 7.179)  | -       |
| Residual SD          | 1.469 (1.234, 1.757)  | -       |
| **Euroimmun S1 IgG ELISA** |           |         |
| Days from onset      | -0.017 (-0.027, -0.008) | <0.001  |
| Intercept            | 6.166 (5.171, 7.161)  | <0.001  |
| Random Intercept SD  | 2.043 (1.583, 2.602)  | -       |
| Residual SD          | 1.274 (1.070, 1.523)  | -       |
| **Genscript cPASS nAb** |                   |         |
| Days from onset      | -0.001 (-0.002, -0.001) | <0.001  |
| Intercept            | 0.828 (0.760, 0.897)  | <0.001  |
| Random Intercept SD  | 0.149 (0.116, 0.188)  | -       |
| Residual SD          | 0.083 (0.070, 0.100)  | -       |
| **Mayo Clinic nAb**  |                       |         |
| Days from onset      | -0.014 (-0.020, -0.008) | <0.001  |
| Intercept            | 9.097 (8.520, 9.672)  | <0.001  |
| Random Intercept SD  | 1.095 (0.840, 1.403)  | -       |
| Residual SD          | 0.767 (0.645, 0.916)  | -       |
| **NeuCovix-HT nAb**  |                       |         |
| Days from onset      | -0.06 (-0.10, -0.03)  | <0.001  |
| Intercept            | 11.02 (7.93, 14.11)   | <0.001  |
| Random Intercept SD  | 6.09 (5.13, 7.23)     | -       |
| Residual SD          | 3.46 (3.02, 3.96)     | -       |

*Two-sided p-values are reported with no correction for multiple testing.

bMayo Clinic nAb was analyzed on the log2 scale.